Merck cuts contractors at NC vax plant; Marksans buys Time-Cap Labs; Attix gets FDA warning;

> Merck ($MRK) acknowledged it is cutting an undisclosed number of contract jobs at a vaccine plant in North Carolina. Report

> India's Marksans Pharma says it has acquired U.S. generics and OTC company, Time-Cap Laboratories for an undisclosed amount. Story

> Novartis ($NVS) is voluntarily recalling about 75,000 packs of asthma drug Foradil Aerolizer that it manufactured at a plant in Switzerland for Merck because the formoterol fumarate inhalation powder was out of spec for particle size during stability tests. Notice and Notice

> Here's a Q&A from ICH about its GMP guidance for API manufacturing. Document (PDF)

> West-Ward is voluntarily recalling 14,649 cartons of fentanyl citrate vials after they failed impurities and degradation specs at 12 months. Report

> German glass and plastic pharmaceutical packaging manufacturer Gerresheimer will sell its borosilicate glass tubing business to Corning for €196 million and then enter into a 10-supply agreement with Corning for the products. Report

> AstraZeneca ($AZN) is recalling 34,524 bottles of Nexium after a pharmacy discovered in a bottle a tablet of the antipsychotic Seroquel XR. Notice

> The FDA has sent a warning letter to Canadian API repackager Attix Pharmaceuticals. Letter

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.